Ardelyx reported its fourth quarter and full year 2024 financial results on February 20, 2025, highlighting significant commercial progress. Total revenue for 2024 reached $333.6 million, including $319.2 million in U.S. Net Product Sales.
IBSRELA's U.S. net product sales revenue for 2024 was $158.3 million, with $53.8 million generated in the fourth quarter, representing approximately 32% growth compared to Q3 2024. The company reaffirmed its full-year 2025 IBSRELA net sales revenue guidance of $240 million to $250 million, maintaining its expectation of over $1 billion in peak annual sales.
XPHOZAH recorded $160.9 million in U.S. net product sales revenue for its first full calendar year of commercialization, including $57.2 million in Q4 2024. Ardelyx reaffirmed its peak annual net sales expectation for XPHOZAH at $750 million. The company ended 2024 with a robust cash position of $250.1 million in cash, cash equivalents, and investments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.